Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neurofibromatosis type 2].

S Goutagny1, D Bouccara, A Bozorg-Grayeli

  • 1Service de neurochirurgie, Service d'ORL, Hôpital Beaujon, APHP, 100 Boulevard du Général Leclerc, 92118 Clichy.

Revue Neurologique
|September 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binaural performance in 155 adults with single-sided or asymmetric profound hearing loss: A STROBE analysis.

European annals of otorhinolaryngology, head and neck diseases·2025
Same author

Dermatologic manifestations in paediatric neurofibromatosis type 2: a cross sectional descriptive multicentric study.

Orphanet journal of rare diseases·2022
Same author

[Meningiomas: A review of current knowledge].

La Revue de medecine interne·2021
Same author

Guidelines of the French Society of Otorhinolaryngology-Head and Neck Surgery (SFORL) and the French Society of Audiology (SFA) for Speech-in-Noise Testing in Adults.

European annals of otorhinolaryngology, head and neck diseases·2021
Same author

Security and reliability of CUSTOMBONE cranioplasties: A prospective multicentric study.

Neuro-Chirurgie·2021
Same author

Guidelines of the French Society of Otorhinolaryngology (SFORL) for teleconsultation in patients with vertigo during the COVID-19 pandemic.

European annals of otorhinolaryngology, head and neck diseases·2020
Same journal

Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study.

Revue neurologique·2026
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
See all related articles

Neurofibromatosis 2 (NF2) is a genetic disorder causing tumors, primarily bilateral vestibular schwannomas. Early surveillance and tailored treatment strategies, including surgery, are crucial for managing NF2 patients.

Area of Science:

  • Genetics
  • Oncology
  • Neurology

Background:

  • Neurofibromatosis 2 (NF2) is a rare autosomal dominant disorder characterized by bilateral vestibular schwannomas.
  • NF2 presents with diverse tumors (schwannomas, meningiomas, ependymomas) affecting the central and peripheral nervous systems, alongside cutaneous and ophthalmological issues.
  • The NF2 gene, encoding Merlin/Schwannomin, is implicated in NF2 and sporadic tumors; its functions are under investigation.

Purpose of the Study:

  • To outline the diagnostic criteria and variable phenotypes of NF2.
  • To identify negative prognostic factors in NF2, such as early symptom onset and high tumor burden.
  • To discuss current and proposed management strategies for NF2.

Main Methods:

  • Review of NF2 diagnostic criteria and clinical manifestations.

Related Experiment Videos

  • Analysis of prognostic factors influencing NF2 progression.
  • Evaluation of treatment options and surveillance protocols for NF2.

    • Main Results:

    • NF2 diagnosis is possible even without bilateral vestibular schwannomas.
    • Young age at onset and numerous tumors are significant negative prognostic indicators.
    • Tumor suppressor gene NF2 (Merlin/Schwannomin) involvement is key, though its functions remain unclear.

    Conclusions:

    • NF2 patient management necessitates specialized oto-neurosurgical teams and mandatory lifelong surveillance.
    • While symptomatic lesions are traditionally treated, an early, proactive approach for vestibular schwannomas is debated to preserve hearing.
    • Surgery is the primary treatment for NF2 tumors, with auditory brainstem implants considered for hearing rehabilitation.